When the interaction between BCR‐ABL and HSP90 is disrupted, the cellular level of BCR‐ABL protein is reduced and the BCR‐ABL1‐STAT5 signaling pathway is thus inhibited,120 suggesting that HSP90 appears to play an essential role in BCR‐ABL mutant leukemia. Here, ABL1 is linked to leukemia.